论文部分内容阅读
目的研究在长春瑞滨（Ｖｉｎｏｒｅｌｂｉｎｅ，ＮＶＢ）加顺铂（Ｃｉｓｐｌａｔｉｎ，ＤＤＰ）方案基础上进一步针对病理学分类和癌细胞分化程度的系列联合化疗方案治疗非小细胞肺癌（ｎｏｎｓｍａｌｃｅｌｌｕｎｇｃａｎｃｅｒ，ＮＳＣＬＣ）的疗效。方法低、中分化程度的肺鳞癌和低分化肺腺癌仍采用基础方案即ＮＶＢ＋ＤＤＰ方案治疗，高分化肺鳞癌在基础方案之上加用博莱霉素（ＢＬＭ），中、高分化肺腺癌在基础方案之上加用多柔比星（阿霉素，ＡＤＭ）。５０例ＮＳＣＬＣ中，男性２７例，女性２３例。腺癌３０例，低、中、高分化程度分别为１３、１１和６例；鳞癌１６例，低、中、高分化程度分别为５、６和５例；混合型病理诊断３例，均为低分化程度。Ⅲｂ期３２例，Ⅳ期１８例。结果完全缓解（ＣＲ）４例，部分缓解（ＰＲ）２９例，稳定（Ｓ）１３例，进展（Ｐ）４例，总有效率为６６％。中位缓解期３９月，ＫａｐｌａｎＭｅｉｅｒ估计半数死亡概率为１２个月。系列方案的剂量限制性毒性为骨髓抑制，发生率为１００％，注药局部反应发生率为４８％。结论ＮＶＢ抗非小细胞肺癌治疗疗效确切，在ＮＶＢ＋ＤＤＰ联合化疗方案中适当增加抗癌药物品种似可增加疗效。
Objective To study the combination of Vinorelbine (NVB) and Cisplatin (DDP) for the treatment of non-smal cell lung cancer (NSCLC). Efficacy. Methods Low and moderately differentiated lung squamous cell carcinomas and poorly differentiated lung adenocarcinomas were treated with the basic regimen of NVB plus DDP. Well-differentiated lung squamous cell carcinomas were treated with bleomycin (BLM) on top of the basic regimen, and moderately and well differentiated lungs were used. Adenocarcinoma plus doxorubicin (adriamycin, ADM) was added to the basic protocol. Of the 50 cases of NSCLC, 27 were male and 23 were female. There were 30 cases of adenocarcinoma with low, medium and high differentiation levels of 13, 11 and 6 cases respectively; 16 cases of squamous cell carcinoma with low, medium and high differentiation levels of 5, 6 and 5 cases respectively; 3 cases of mixed type pathological diagnosis. For poor differentiation. There were 32 cases in stage IIIb and 18 cases in stage IV. Results There were 4 cases of complete remission (CR), 29 cases of partial remission (PR), 13 cases of stable (S), and 4 cases of progressive (P). The total effective rate was 66%. In the median remission period of March to September, Kaplan-Meier estimated that the half-life probability was 12 months. The dose-limiting toxicity of the series regimen was myelosuppression with an incidence of 100% and a local reaction rate of 48%. Conclusion The curative effect of NVB against non-small cell lung cancer is definite. Appropriate increase of anticancer drugs in NVB plus DDP combined chemotherapy regimen may increase the therapeutic effect.